| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Waldenstrom Macroglobulinemia | 139 | 2024 | 1073 | 33.750 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 44 | 2024 | 1405 | 9.650 |
Why?
|
| Myeloid Differentiation Factor 88 | 55 | 2024 | 586 | 8.180 |
Why?
|
| Adenine | 48 | 2024 | 986 | 6.840 |
Why?
|
| Receptors, CXCR4 | 33 | 2024 | 727 | 6.010 |
Why?
|
| Piperidines | 52 | 2024 | 1656 | 5.510 |
Why?
|
| Pyrazoles | 41 | 2024 | 2007 | 5.390 |
Why?
|
| Pyrimidines | 42 | 2024 | 3024 | 4.790 |
Why?
|
| Lymphoma, B-Cell | 14 | 2024 | 940 | 4.630 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 62 | 2024 | 11729 | 4.360 |
Why?
|
| Protein Kinase Inhibitors | 32 | 2024 | 5662 | 3.820 |
Why?
|
| Lymphoma, AIDS-Related | 11 | 2016 | 79 | 3.590 |
Why?
|
| Epstein-Barr Virus Infections | 12 | 2024 | 611 | 3.310 |
Why?
|
| Immunoglobulin M | 23 | 2023 | 1530 | 3.150 |
Why?
|
| Antineoplastic Agents | 41 | 2023 | 13616 | 2.950 |
Why?
|
| Multiple Myeloma | 32 | 2024 | 5143 | 2.890 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 8 | 2023 | 124 | 2.570 |
Why?
|
| Vincristine | 22 | 2024 | 1036 | 2.220 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 7 | 2022 | 178 | 2.030 |
Why?
|
| Cyclophosphamide | 26 | 2024 | 2218 | 2.030 |
Why?
|
| Lymphoma, Non-Hodgkin | 12 | 2015 | 1373 | 1.950 |
Why?
|
| Antigens, CD20 | 10 | 2019 | 201 | 1.920 |
Why?
|
| Prognosis | 72 | 2024 | 29551 | 1.860 |
Why?
|
| Prednisone | 20 | 2024 | 1564 | 1.820 |
Why?
|
| Doxorubicin | 24 | 2024 | 2215 | 1.800 |
Why?
|
| SEER Program | 12 | 2018 | 1449 | 1.670 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 11 | 2018 | 694 | 1.600 |
Why?
|
| Herpesvirus 4, Human | 12 | 2024 | 1078 | 1.550 |
Why?
|
| Lymphoproliferative Disorders | 5 | 2023 | 533 | 1.530 |
Why?
|
| Mutation | 49 | 2024 | 30025 | 1.530 |
Why?
|
| Humans | 309 | 2024 | 760437 | 1.480 |
Why?
|
| Hodgkin Disease | 6 | 2016 | 1378 | 1.420 |
Why?
|
| Leukemia-Lymphoma, Adult T-Cell | 5 | 2021 | 164 | 1.410 |
Why?
|
| Monoclonal Gammopathy of Undetermined Significance | 5 | 2022 | 179 | 1.400 |
Why?
|
| Aged | 125 | 2024 | 168840 | 1.370 |
Why?
|
| Paraproteinemias | 5 | 2022 | 248 | 1.340 |
Why?
|
| Survival Rate | 29 | 2024 | 12698 | 1.310 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 10 | 2024 | 1640 | 1.270 |
Why?
|
| B-Lymphocytes | 13 | 2023 | 4748 | 1.250 |
Why?
|
| Survival Analysis | 29 | 2020 | 10075 | 1.230 |
Why?
|
| Lymphoma, Primary Effusion | 3 | 2020 | 17 | 1.210 |
Why?
|
| Lymphoma | 10 | 2021 | 1901 | 1.210 |
Why?
|
| Middle Aged | 126 | 2024 | 220382 | 1.210 |
Why?
|
| Aged, 80 and over | 66 | 2024 | 58859 | 1.180 |
Why?
|
| Disease Management | 12 | 2024 | 2501 | 1.150 |
Why?
|
| Neoplasms, Second Primary | 6 | 2020 | 1051 | 1.140 |
Why?
|
| Plasma Cells | 7 | 2023 | 599 | 1.100 |
Why?
|
| Treatment Outcome | 55 | 2024 | 64591 | 1.090 |
Why?
|
| Lymphocytes | 4 | 2020 | 2610 | 1.070 |
Why?
|
| Herpesvirus 8, Human | 3 | 2020 | 255 | 1.070 |
Why?
|
| Lymphoma, Large-Cell, Immunoblastic | 3 | 2011 | 25 | 1.050 |
Why?
|
| Male | 145 | 2024 | 360035 | 1.040 |
Why?
|
| Bone Marrow | 13 | 2023 | 2907 | 1.030 |
Why?
|
| Neoplasm Proteins | 6 | 2021 | 3610 | 1.020 |
Why?
|
| Lymphoma, Follicular | 2 | 2024 | 457 | 1.010 |
Why?
|
| Antibodies, Monoclonal | 14 | 2024 | 9176 | 0.980 |
Why?
|
| Central Nervous System Neoplasms | 5 | 2016 | 916 | 0.980 |
Why?
|
| Disease-Free Survival | 20 | 2020 | 6813 | 0.970 |
Why?
|
| Female | 141 | 2024 | 391875 | 0.950 |
Why?
|
| Leukemia, Plasma Cell | 3 | 2022 | 46 | 0.950 |
Why?
|
| Molecular Targeted Therapy | 8 | 2024 | 2805 | 0.940 |
Why?
|
| Quinazolinones | 3 | 2016 | 221 | 0.930 |
Why?
|
| Adult | 98 | 2024 | 220781 | 0.920 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 4 | 2021 | 168 | 0.910 |
Why?
|
| Sulfonamides | 3 | 2024 | 1973 | 0.910 |
Why?
|
| Etoposide | 6 | 2024 | 634 | 0.890 |
Why?
|
| Antiretroviral Therapy, Highly Active | 8 | 2016 | 1896 | 0.880 |
Why?
|
| Antineoplastic Agents, Alkylating | 4 | 2020 | 617 | 0.870 |
Why?
|
| Salvage Therapy | 7 | 2022 | 1264 | 0.870 |
Why?
|
| Protein-Tyrosine Kinases | 7 | 2023 | 2423 | 0.840 |
Why?
|
| Erythrocyte Indices | 2 | 2023 | 144 | 0.830 |
Why?
|
| Kaplan-Meier Estimate | 15 | 2020 | 6471 | 0.830 |
Why?
|
| Purines | 3 | 2016 | 605 | 0.830 |
Why?
|
| Burkitt Lymphoma | 3 | 2013 | 335 | 0.820 |
Why?
|
| Immunotherapy | 9 | 2024 | 4649 | 0.790 |
Why?
|
| Ifosfamide | 1 | 2022 | 232 | 0.780 |
Why?
|
| Hyponatremia | 2 | 2016 | 279 | 0.780 |
Why?
|
| Neutrophils | 4 | 2020 | 3764 | 0.770 |
Why?
|
| Leukemia | 4 | 2014 | 1522 | 0.750 |
Why?
|
| Herpesviridae Infections | 2 | 2020 | 270 | 0.740 |
Why?
|
| Blood Viscosity | 2 | 2019 | 124 | 0.720 |
Why?
|
| HIV Infections | 14 | 2023 | 17328 | 0.710 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2023 | 237 | 0.710 |
Why?
|
| Leukemia, Myeloid, Acute | 7 | 2015 | 3610 | 0.700 |
Why?
|
| Proto-Oncogene Proteins c-hck | 5 | 2022 | 46 | 0.700 |
Why?
|
| Pyrazines | 5 | 2021 | 1199 | 0.660 |
Why?
|
| Retrospective Studies | 46 | 2024 | 80430 | 0.630 |
Why?
|
| Human T-lymphotropic virus 1 | 2 | 2021 | 142 | 0.620 |
Why?
|
| Mutation, Missense | 2 | 2019 | 2571 | 0.620 |
Why?
|
| Stem Cell Transplantation | 6 | 2018 | 1598 | 0.620 |
Why?
|
| Cell Transformation, Neoplastic | 3 | 2017 | 2821 | 0.610 |
Why?
|
| Pleural Effusion, Malignant | 2 | 2016 | 106 | 0.600 |
Why?
|
| Nervous System | 1 | 2021 | 543 | 0.590 |
Why?
|
| Neoplasm Staging | 17 | 2019 | 11096 | 0.550 |
Why?
|
| Neutropenia | 2 | 2012 | 884 | 0.550 |
Why?
|
| beta 2-Microglobulin | 3 | 2020 | 329 | 0.530 |
Why?
|
| Hematologic Neoplasms | 4 | 2014 | 1890 | 0.530 |
Why?
|
| HIV Seropositivity | 2 | 2013 | 960 | 0.530 |
Why?
|
| Signal Transduction | 15 | 2024 | 23397 | 0.520 |
Why?
|
| Chile | 4 | 2024 | 256 | 0.510 |
Why?
|
| Combined Modality Therapy | 12 | 2020 | 8522 | 0.510 |
Why?
|
| L-Lactate Dehydrogenase | 3 | 2024 | 411 | 0.510 |
Why?
|
| Smoking | 4 | 2014 | 9046 | 0.510 |
Why?
|
| Incidence | 17 | 2021 | 21322 | 0.500 |
Why?
|
| Anti-Retroviral Agents | 2 | 2016 | 1781 | 0.500 |
Why?
|
| Daunorubicin | 1 | 2015 | 156 | 0.490 |
Why?
|
| Boronic Acids | 3 | 2015 | 914 | 0.470 |
Why?
|
| Dexamethasone | 6 | 2023 | 1944 | 0.460 |
Why?
|
| Skin Neoplasms | 4 | 2021 | 5815 | 0.460 |
Why?
|
| von Willebrand Factor | 1 | 2018 | 673 | 0.460 |
Why?
|
| Age Factors | 10 | 2018 | 18379 | 0.460 |
Why?
|
| Drug Tolerance | 1 | 2015 | 367 | 0.450 |
Why?
|
| Myxoma | 1 | 2014 | 114 | 0.450 |
Why?
|
| Withholding Treatment | 1 | 2018 | 617 | 0.440 |
Why?
|
| Acidosis, Lactic | 1 | 2015 | 145 | 0.440 |
Why?
|
| Latin America | 4 | 2023 | 410 | 0.440 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2018 | 625 | 0.430 |
Why?
|
| Disease Progression | 11 | 2021 | 13484 | 0.420 |
Why?
|
| Erythrocyte Membrane | 1 | 2014 | 439 | 0.420 |
Why?
|
| Hyperammonemia | 1 | 2013 | 76 | 0.410 |
Why?
|
| Pleural Cavity | 1 | 2012 | 25 | 0.410 |
Why?
|
| Young Adult | 24 | 2024 | 59068 | 0.410 |
Why?
|
| Diagnosis, Differential | 9 | 2024 | 12969 | 0.410 |
Why?
|
| Lymphoma, T-Cell, Cutaneous | 1 | 2014 | 212 | 0.400 |
Why?
|
| Peritoneal Cavity | 1 | 2012 | 135 | 0.400 |
Why?
|
| Follow-Up Studies | 18 | 2021 | 39078 | 0.400 |
Why?
|
| Central Nervous System Diseases | 1 | 2016 | 520 | 0.390 |
Why?
|
| Proportional Hazards Models | 8 | 2021 | 12429 | 0.390 |
Why?
|
| Acquired Immunodeficiency Syndrome | 2 | 2020 | 2199 | 0.390 |
Why?
|
| Immunoblastic Lymphadenopathy | 1 | 2011 | 40 | 0.380 |
Why?
|
| Insurance Claim Review | 1 | 2016 | 735 | 0.380 |
Why?
|
| Peru | 5 | 2021 | 890 | 0.380 |
Why?
|
| Prospective Studies | 17 | 2023 | 54339 | 0.380 |
Why?
|
| Leukocyte Count | 1 | 2015 | 1596 | 0.370 |
Why?
|
| Dura Mater | 1 | 2013 | 290 | 0.370 |
Why?
|
| Receptors, Interleukin-2 | 1 | 2012 | 562 | 0.370 |
Why?
|
| Heart Neoplasms | 1 | 2014 | 362 | 0.370 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 9 | 2022 | 5663 | 0.360 |
Why?
|
| Immunophenotyping | 5 | 2021 | 1870 | 0.360 |
Why?
|
| Thalidomide | 2 | 2022 | 885 | 0.360 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2014 | 590 | 0.350 |
Why?
|
| HIV Seronegativity | 1 | 2011 | 211 | 0.350 |
Why?
|
| Sarcoma, Myeloid | 1 | 2010 | 51 | 0.350 |
Why?
|
| Fatty Acids | 2 | 2014 | 1805 | 0.340 |
Why?
|
| Kidney Diseases | 2 | 2021 | 2093 | 0.340 |
Why?
|
| Drug Resistance, Neoplasm | 8 | 2024 | 5292 | 0.330 |
Why?
|
| Risk Factors | 22 | 2022 | 74055 | 0.330 |
Why?
|
| Peripheral Nervous System Diseases | 2 | 2017 | 710 | 0.330 |
Why?
|
| Fatal Outcome | 4 | 2021 | 1832 | 0.320 |
Why?
|
| Genomics | 6 | 2024 | 5806 | 0.310 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 3 | 2021 | 1404 | 0.310 |
Why?
|
| Biopsy | 6 | 2018 | 6765 | 0.310 |
Why?
|
| Mouth | 1 | 2011 | 380 | 0.310 |
Why?
|
| Lymphopenia | 1 | 2010 | 280 | 0.310 |
Why?
|
| Immunoglobulin G | 4 | 2018 | 4549 | 0.310 |
Why?
|
| Cohort Studies | 14 | 2021 | 41366 | 0.310 |
Why?
|
| Clinical Trials as Topic | 8 | 2020 | 7996 | 0.300 |
Why?
|
| Pregnancy Complications, Hematologic | 1 | 2009 | 179 | 0.300 |
Why?
|
| Boron Compounds | 2 | 2020 | 182 | 0.300 |
Why?
|
| Albumins | 1 | 2010 | 575 | 0.290 |
Why?
|
| Kidney | 2 | 2021 | 7046 | 0.290 |
Why?
|
| High-Throughput Nucleotide Sequencing | 3 | 2021 | 3631 | 0.290 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 2010 | 439 | 0.290 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2009 | 255 | 0.290 |
Why?
|
| Syndrome | 4 | 2018 | 3267 | 0.290 |
Why?
|
| Obesity | 3 | 2015 | 12918 | 0.280 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2011 | 1351 | 0.280 |
Why?
|
| Case-Control Studies | 11 | 2020 | 22097 | 0.270 |
Why?
|
| Immunotherapy, Adoptive | 3 | 2024 | 1463 | 0.270 |
Why?
|
| United States | 18 | 2021 | 72202 | 0.270 |
Why?
|
| Immunoconjugates | 1 | 2014 | 953 | 0.270 |
Why?
|
| Lymphocyte Count | 4 | 2021 | 778 | 0.270 |
Why?
|
| Algorithms | 4 | 2017 | 14002 | 0.270 |
Why?
|
| Amino Acid Substitution | 4 | 2019 | 1737 | 0.260 |
Why?
|
| Glycine | 2 | 2020 | 665 | 0.260 |
Why?
|
| Risk Assessment | 9 | 2024 | 23953 | 0.260 |
Why?
|
| Mouth Neoplasms | 1 | 2011 | 595 | 0.260 |
Why?
|
| Anemia, Hemolytic, Autoimmune | 2 | 2021 | 147 | 0.260 |
Why?
|
| Medical Oncology | 7 | 2023 | 2318 | 0.250 |
Why?
|
| Transplantation, Autologous | 6 | 2022 | 2113 | 0.250 |
Why?
|
| Amyloidosis | 2 | 2023 | 817 | 0.250 |
Why?
|
| Remission Induction | 6 | 2014 | 2394 | 0.250 |
Why?
|
| Databases, Factual | 4 | 2017 | 7948 | 0.250 |
Why?
|
| Registries | 3 | 2020 | 8216 | 0.250 |
Why?
|
| Erythrocyte Transfusion | 1 | 2010 | 565 | 0.250 |
Why?
|
| Drug Resistance | 2 | 2023 | 1597 | 0.250 |
Why?
|
| Lymph Nodes | 5 | 2021 | 3469 | 0.250 |
Why?
|
| Clostridium Infections | 1 | 2012 | 558 | 0.240 |
Why?
|
| Neoplasms | 5 | 2016 | 22083 | 0.240 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 1 | 2009 | 242 | 0.240 |
Why?
|
| Benzamides | 2 | 2021 | 1370 | 0.240 |
Why?
|
| Adolescent | 18 | 2022 | 88196 | 0.230 |
Why?
|
| Neoplastic Cells, Circulating | 2 | 2022 | 940 | 0.230 |
Why?
|
| Chromosome Deletion | 2 | 2020 | 1387 | 0.230 |
Why?
|
| Brain Diseases | 1 | 2013 | 1544 | 0.230 |
Why?
|
| Overweight | 2 | 2013 | 2412 | 0.230 |
Why?
|
| Bleomycin | 2 | 2014 | 494 | 0.220 |
Why?
|
| Antigens, CD19 | 2 | 2024 | 425 | 0.210 |
Why?
|
| Biomedical Research | 1 | 2018 | 3421 | 0.210 |
Why?
|
| Vinblastine | 2 | 2014 | 488 | 0.210 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2015 | 2204 | 0.210 |
Why?
|
| Plasmacytoma | 2 | 2020 | 171 | 0.200 |
Why?
|
| POEMS Syndrome | 1 | 2021 | 12 | 0.200 |
Why?
|
| Population Surveillance | 4 | 2017 | 2603 | 0.200 |
Why?
|
| Hematology | 2 | 2019 | 244 | 0.200 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2014 | 2163 | 0.190 |
Why?
|
| Immunosuppressive Agents | 1 | 2014 | 4168 | 0.190 |
Why?
|
| Cyanosis | 1 | 2021 | 86 | 0.190 |
Why?
|
| T-Lymphocytes | 3 | 2024 | 10188 | 0.190 |
Why?
|
| Dacarbazine | 2 | 2014 | 559 | 0.190 |
Why?
|
| CD40 Ligand | 1 | 2023 | 526 | 0.190 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2021 | 10759 | 0.190 |
Why?
|
| Immunoglobulin kappa-Chains | 1 | 2021 | 169 | 0.180 |
Why?
|
| Vidarabine | 2 | 2013 | 336 | 0.180 |
Why?
|
| Rhode Island | 2 | 2013 | 351 | 0.180 |
Why?
|
| Immunohistochemistry | 4 | 2021 | 11070 | 0.180 |
Why?
|
| Review Literature as Topic | 2 | 2013 | 347 | 0.180 |
Why?
|
| Age of Onset | 2 | 2018 | 3302 | 0.180 |
Why?
|
| Biology | 1 | 2022 | 289 | 0.180 |
Why?
|
| Recurrence | 5 | 2019 | 8466 | 0.180 |
Why?
|
| Antigens, Neoplasm | 1 | 2008 | 1994 | 0.180 |
Why?
|
| Paraproteins | 1 | 2020 | 38 | 0.170 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2023 | 9267 | 0.170 |
Why?
|
| Primary Health Care | 1 | 2016 | 4674 | 0.170 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2021 | 2860 | 0.170 |
Why?
|
| Chromosome Aberrations | 2 | 2016 | 1771 | 0.170 |
Why?
|
| CD4 Lymphocyte Count | 3 | 2011 | 2569 | 0.170 |
Why?
|
| Herpes Zoster | 1 | 2022 | 253 | 0.170 |
Why?
|
| Edema | 1 | 2023 | 769 | 0.160 |
Why?
|
| Odds Ratio | 3 | 2019 | 9639 | 0.160 |
Why?
|
| Therapies, Investigational | 1 | 2020 | 111 | 0.160 |
Why?
|
| Carboplatin | 1 | 2022 | 793 | 0.160 |
Why?
|
| Point Mutation | 2 | 2021 | 1595 | 0.160 |
Why?
|
| Portraits as Topic | 1 | 2018 | 32 | 0.160 |
Why?
|
| Flaviviridae | 1 | 2018 | 9 | 0.160 |
Why?
|
| Flaviviridae Infections | 1 | 2018 | 7 | 0.160 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2020 | 373 | 0.160 |
Why?
|
| Colorectal Neoplasms | 2 | 2016 | 6894 | 0.160 |
Why?
|
| Models, Biological | 1 | 2014 | 9462 | 0.150 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2012 | 3072 | 0.150 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2020 | 452 | 0.150 |
Why?
|
| Cell Proliferation | 3 | 2022 | 10425 | 0.150 |
Why?
|
| Brain Neoplasms | 1 | 2019 | 9003 | 0.150 |
Why?
|
| Logistic Models | 3 | 2020 | 13240 | 0.150 |
Why?
|
| Pleura | 1 | 2019 | 244 | 0.150 |
Why?
|
| Medicare | 4 | 2020 | 6732 | 0.150 |
Why?
|
| Amyloid | 1 | 2023 | 840 | 0.150 |
Why?
|
| Consensus | 3 | 2023 | 3115 | 0.140 |
Why?
|
| Chemokine CXCL13 | 1 | 2017 | 59 | 0.140 |
Why?
|
| Wounds and Injuries | 1 | 2010 | 2483 | 0.140 |
Why?
|
| Alkylating Agents | 1 | 2017 | 133 | 0.140 |
Why?
|
| Atrial Fibrillation | 1 | 2016 | 5126 | 0.140 |
Why?
|
| Interleukin-1 Receptor-Associated Kinases | 1 | 2017 | 76 | 0.140 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 2018 | 242 | 0.140 |
Why?
|
| Sex Factors | 3 | 2017 | 10538 | 0.140 |
Why?
|
| Pathology, Molecular | 1 | 2020 | 328 | 0.140 |
Why?
|
| Autoimmune Diseases | 1 | 2009 | 2247 | 0.140 |
Why?
|
| Plasmapheresis | 1 | 2017 | 206 | 0.140 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2018 | 8519 | 0.130 |
Why?
|
| Quality of Life | 3 | 2024 | 13338 | 0.130 |
Why?
|
| Practice Guidelines as Topic | 3 | 2020 | 7380 | 0.130 |
Why?
|
| Paracrine Communication | 1 | 2018 | 276 | 0.130 |
Why?
|
| von Willebrand Diseases | 1 | 2018 | 132 | 0.130 |
Why?
|
| Animals | 11 | 2021 | 168253 | 0.130 |
Why?
|
| Multivariate Analysis | 4 | 2015 | 12054 | 0.130 |
Why?
|
| London | 1 | 2016 | 234 | 0.130 |
Why?
|
| Ligands | 1 | 2023 | 3270 | 0.130 |
Why?
|
| Adaptor Proteins, Signal Transducing | 4 | 2022 | 2895 | 0.130 |
Why?
|
| Infectious Mononucleosis | 1 | 2016 | 133 | 0.130 |
Why?
|
| Amyloid Neuropathies, Familial | 1 | 2018 | 150 | 0.130 |
Why?
|
| Lung Injury | 1 | 2020 | 422 | 0.130 |
Why?
|
| Bone and Bones | 2 | 2017 | 2566 | 0.120 |
Why?
|
| Body Surface Area | 1 | 2015 | 197 | 0.120 |
Why?
|
| Histocytochemistry | 1 | 2016 | 698 | 0.120 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 2 | 2021 | 1624 | 0.120 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2011 | 1337 | 0.120 |
Why?
|
| Hydroa Vacciniforme | 1 | 2014 | 2 | 0.120 |
Why?
|
| Protein Multimerization | 2 | 2017 | 982 | 0.120 |
Why?
|
| Liver Function Tests | 1 | 2016 | 522 | 0.120 |
Why?
|
| Time Factors | 5 | 2021 | 39947 | 0.120 |
Why?
|
| Neoplasms, Adnexal and Skin Appendage | 1 | 2014 | 27 | 0.120 |
Why?
|
| Leucine | 1 | 2016 | 548 | 0.120 |
Why?
|
| Proline | 1 | 2016 | 457 | 0.120 |
Why?
|
| Translocation, Genetic | 2 | 2020 | 1388 | 0.120 |
Why?
|
| Virus Activation | 1 | 2016 | 322 | 0.110 |
Why?
|
| Kidney Function Tests | 1 | 2016 | 675 | 0.110 |
Why?
|
| Lung Neoplasms | 2 | 2016 | 13312 | 0.110 |
Why?
|
| Subcutaneous Tissue | 1 | 2014 | 132 | 0.110 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2024 | 2248 | 0.110 |
Why?
|
| Databases, Bibliographic | 1 | 2014 | 130 | 0.110 |
Why?
|
| Toll-Like Receptors | 1 | 2017 | 589 | 0.110 |
Why?
|
| HTLV-I Infections | 1 | 2014 | 103 | 0.110 |
Why?
|
| Organ Specificity | 2 | 2019 | 1956 | 0.110 |
Why?
|
| Breast Neoplasms | 3 | 2016 | 20985 | 0.110 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2019 | 36362 | 0.110 |
Why?
|
| Codon, Nonsense | 1 | 2014 | 285 | 0.110 |
Why?
|
| Risk | 2 | 2016 | 9605 | 0.110 |
Why?
|
| Neoplasm Regression, Spontaneous | 1 | 2013 | 46 | 0.110 |
Why?
|
| Skin Diseases | 1 | 2022 | 1090 | 0.110 |
Why?
|
| DNA Mutational Analysis | 2 | 2021 | 4108 | 0.110 |
Why?
|
| Parvoviridae Infections | 1 | 2012 | 36 | 0.100 |
Why?
|
| Parvovirus B19, Human | 1 | 2012 | 40 | 0.100 |
Why?
|
| Frameshift Mutation | 1 | 2014 | 392 | 0.100 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 2016 | 545 | 0.100 |
Why?
|
| Eye Neoplasms | 1 | 2014 | 307 | 0.100 |
Why?
|
| Cerebrospinal Fluid | 1 | 2015 | 544 | 0.100 |
Why?
|
| Prostatic Neoplasms | 1 | 2015 | 11095 | 0.100 |
Why?
|
| Tattooing | 1 | 2012 | 57 | 0.100 |
Why?
|
| Hypovolemia | 1 | 2012 | 48 | 0.100 |
Why?
|
| Arginine Vasopressin | 1 | 2012 | 125 | 0.100 |
Why?
|
| Splenic Neoplasms | 1 | 2012 | 94 | 0.100 |
Why?
|
| Inappropriate ADH Syndrome | 1 | 2012 | 61 | 0.100 |
Why?
|
| Propensity Score | 1 | 2020 | 1906 | 0.100 |
Why?
|
| Receptors, Vasopressin | 1 | 2012 | 106 | 0.100 |
Why?
|
| Immunoglobulin E | 1 | 2018 | 1494 | 0.100 |
Why?
|
| Advisory Committees | 1 | 2016 | 783 | 0.100 |
Why?
|
| Lymphocytosis | 1 | 2013 | 121 | 0.100 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2014 | 614 | 0.100 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2016 | 422 | 0.100 |
Why?
|
| Immunocompetence | 1 | 2011 | 138 | 0.090 |
Why?
|
| Asia | 1 | 2013 | 618 | 0.090 |
Why?
|
| DNA Copy Number Variations | 1 | 2020 | 2017 | 0.090 |
Why?
|
| MAP Kinase Signaling System | 1 | 2018 | 1485 | 0.090 |
Why?
|
| Epidemiologic Studies | 1 | 2014 | 674 | 0.090 |
Why?
|
| Blood Proteins | 1 | 2016 | 1174 | 0.090 |
Why?
|
| Anemia, Aplastic | 1 | 2012 | 228 | 0.090 |
Why?
|
| Viral Load | 2 | 2011 | 3329 | 0.090 |
Why?
|
| Leukemic Infiltration | 1 | 2010 | 47 | 0.090 |
Why?
|
| Nervous System Diseases | 1 | 2021 | 1654 | 0.090 |
Why?
|
| Benzazepines | 1 | 2012 | 310 | 0.090 |
Why?
|
| Tumor Microenvironment | 1 | 2023 | 3874 | 0.090 |
Why?
|
| Hospitals | 1 | 2023 | 3873 | 0.090 |
Why?
|
| Breast Implants | 1 | 2013 | 411 | 0.080 |
Why?
|
| Blood-Brain Barrier | 1 | 2016 | 1024 | 0.080 |
Why?
|
| Leukapheresis | 1 | 2009 | 134 | 0.080 |
Why?
|
| Hepatitis B virus | 1 | 2013 | 528 | 0.080 |
Why?
|
| Antibodies, Neoplasm | 1 | 2011 | 281 | 0.080 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2015 | 1135 | 0.080 |
Why?
|
| Cell Transformation, Viral | 1 | 2011 | 526 | 0.080 |
Why?
|
| Public Health | 1 | 2022 | 2665 | 0.080 |
Why?
|
| Radiotherapy | 1 | 2016 | 1498 | 0.080 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2012 | 629 | 0.080 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2010 | 213 | 0.080 |
Why?
|
| Decision Support Techniques | 1 | 2019 | 1998 | 0.080 |
Why?
|
| False Positive Reactions | 1 | 2011 | 956 | 0.080 |
Why?
|
| Pregnancy Trimesters | 1 | 2009 | 197 | 0.080 |
Why?
|
| Graves Disease | 1 | 2010 | 238 | 0.080 |
Why?
|
| Oligopeptides | 1 | 2014 | 1186 | 0.080 |
Why?
|
| Venous Thromboembolism | 1 | 2022 | 1863 | 0.080 |
Why?
|
| Lung | 2 | 2019 | 9973 | 0.080 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2018 | 10180 | 0.080 |
Why?
|
| Membrane Proteins | 2 | 2016 | 7849 | 0.080 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 2012 | 369 | 0.080 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 1 | 2010 | 130 | 0.080 |
Why?
|
| Pesticides | 1 | 2011 | 294 | 0.080 |
Why?
|
| Apoptosis | 4 | 2020 | 9468 | 0.070 |
Why?
|
| Antiemetics | 1 | 2009 | 186 | 0.070 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2018 | 2911 | 0.070 |
Why?
|
| Protein Binding | 2 | 2017 | 9340 | 0.070 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2012 | 12127 | 0.070 |
Why?
|
| Postoperative Complications | 1 | 2010 | 15627 | 0.070 |
Why?
|
| Hepatitis B | 1 | 2013 | 706 | 0.070 |
Why?
|
| Pericardium | 1 | 2012 | 675 | 0.070 |
Why?
|
| Neoplasm Invasiveness | 1 | 2016 | 3587 | 0.070 |
Why?
|
| Down-Regulation | 1 | 2015 | 2911 | 0.070 |
Why?
|
| Sirolimus | 1 | 2015 | 1533 | 0.070 |
Why?
|
| Drug Administration Schedule | 1 | 2015 | 4849 | 0.070 |
Why?
|
| Germ-Line Mutation | 1 | 2016 | 1850 | 0.070 |
Why?
|
| Cluster Analysis | 1 | 2014 | 2711 | 0.070 |
Why?
|
| Periodicals as Topic | 1 | 2018 | 1463 | 0.070 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2011 | 897 | 0.070 |
Why?
|
| Boston | 2 | 2019 | 9326 | 0.070 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2013 | 1089 | 0.070 |
Why?
|
| Bone Neoplasms | 1 | 2019 | 2525 | 0.070 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2010 | 488 | 0.070 |
Why?
|
| Patient Selection | 2 | 2018 | 4240 | 0.070 |
Why?
|
| Abnormalities, Drug-Induced | 1 | 2009 | 339 | 0.070 |
Why?
|
| Phenotype | 2 | 2016 | 16585 | 0.070 |
Why?
|
| Sodium | 1 | 2012 | 1589 | 0.070 |
Why?
|
| NF-kappa B | 3 | 2020 | 2485 | 0.070 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2022 | 3159 | 0.070 |
Why?
|
| Gene Expression | 1 | 2019 | 7582 | 0.070 |
Why?
|
| Antibody Specificity | 1 | 2008 | 1060 | 0.070 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2015 | 2008 | 0.070 |
Why?
|
| Genotype | 2 | 2017 | 12976 | 0.070 |
Why?
|
| Europe | 1 | 2013 | 3419 | 0.060 |
Why?
|
| Drug Interactions | 1 | 2010 | 1415 | 0.060 |
Why?
|
| Skin | 1 | 2019 | 4474 | 0.060 |
Why?
|
| Membrane Glycoproteins | 1 | 2016 | 3701 | 0.060 |
Why?
|
| Truth Disclosure | 1 | 2009 | 433 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2014 | 2453 | 0.060 |
Why?
|
| Kidney Neoplasms | 1 | 2022 | 4241 | 0.060 |
Why?
|
| Child | 6 | 2018 | 80086 | 0.060 |
Why?
|
| Thyroidectomy | 1 | 2010 | 907 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2016 | 17854 | 0.060 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2009 | 591 | 0.060 |
Why?
|
| Fever | 1 | 2012 | 1618 | 0.060 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2014 | 1393 | 0.060 |
Why?
|
| Iron | 1 | 2012 | 1787 | 0.060 |
Why?
|
| Regression Analysis | 1 | 2013 | 6340 | 0.060 |
Why?
|
| Child, Preschool | 4 | 2010 | 42209 | 0.060 |
Why?
|
| Abortion, Induced | 1 | 2009 | 462 | 0.060 |
Why?
|
| Clinical Protocols | 1 | 2009 | 1438 | 0.060 |
Why?
|
| Central Nervous System | 2 | 2022 | 1337 | 0.060 |
Why?
|
| Host-Pathogen Interactions | 1 | 2012 | 1454 | 0.050 |
Why?
|
| Antiviral Agents | 1 | 2016 | 3066 | 0.050 |
Why?
|
| Models, Theoretical | 1 | 2015 | 3576 | 0.050 |
Why?
|
| Comorbidity | 1 | 2017 | 10494 | 0.050 |
Why?
|
| Cross Infection | 1 | 2012 | 1438 | 0.050 |
Why?
|
| World Health Organization | 1 | 2008 | 1315 | 0.050 |
Why?
|
| MicroRNAs | 1 | 2018 | 3796 | 0.050 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3080 | 0.050 |
Why?
|
| Data Interpretation, Statistical | 1 | 2012 | 2691 | 0.050 |
Why?
|
| Cell Line, Tumor | 4 | 2021 | 16945 | 0.050 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2015 | 4509 | 0.050 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3200 | 0.050 |
Why?
|
| Cell Survival | 3 | 2018 | 5790 | 0.050 |
Why?
|
| Transplantation, Homologous | 1 | 2010 | 4808 | 0.050 |
Why?
|
| Inflammation | 1 | 2021 | 10746 | 0.050 |
Why?
|
| Cesarean Section | 1 | 2009 | 1393 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 2 | 2021 | 6128 | 0.050 |
Why?
|
| Early Detection of Cancer | 1 | 2015 | 3183 | 0.050 |
Why?
|
| Argentina | 1 | 2021 | 245 | 0.050 |
Why?
|
| Cell Line | 2 | 2018 | 15598 | 0.040 |
Why?
|
| Colombia | 1 | 2021 | 279 | 0.040 |
Why?
|
| Ulcer | 1 | 2022 | 204 | 0.040 |
Why?
|
| Drug Delivery Systems | 1 | 2012 | 2224 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2016 | 14565 | 0.040 |
Why?
|
| Flow Cytometry | 1 | 2010 | 5865 | 0.040 |
Why?
|
| Reproducibility of Results | 2 | 2015 | 20078 | 0.040 |
Why?
|
| United States Food and Drug Administration | 1 | 2008 | 1663 | 0.040 |
Why?
|
| Phospholipase C gamma | 1 | 2020 | 130 | 0.040 |
Why?
|
| Acute Disease | 1 | 2010 | 7230 | 0.040 |
Why?
|
| Molecular Biology | 1 | 2023 | 580 | 0.040 |
Why?
|
| src-Family Kinases | 1 | 2022 | 535 | 0.040 |
Why?
|
| Immunologic Factors | 2 | 2019 | 1588 | 0.040 |
Why?
|
| Infant | 3 | 2010 | 36183 | 0.040 |
Why?
|
| Pregnancy Outcome | 1 | 2009 | 2916 | 0.040 |
Why?
|
| Mice | 3 | 2021 | 81402 | 0.040 |
Why?
|
| Positron-Emission Tomography | 1 | 2015 | 6475 | 0.040 |
Why?
|
| Upper Extremity | 1 | 2023 | 656 | 0.040 |
Why?
|
| Hemoglobins | 2 | 2015 | 1524 | 0.040 |
Why?
|
| Pneumocystis carinii | 1 | 2018 | 72 | 0.040 |
Why?
|
| Technetium | 1 | 2018 | 322 | 0.040 |
Why?
|
| Body Mass Index | 1 | 2015 | 12932 | 0.040 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2016 | 5296 | 0.040 |
Why?
|
| Cytogenetic Analysis | 1 | 2018 | 270 | 0.040 |
Why?
|
| Education, Medical, Graduate | 1 | 2009 | 2367 | 0.040 |
Why?
|
| Mice, Inbred NOD | 1 | 2021 | 1824 | 0.040 |
Why?
|
| Calcium | 1 | 2010 | 5726 | 0.040 |
Why?
|
| Interferon-alpha | 1 | 2021 | 920 | 0.040 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2023 | 2509 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2021 | 2625 | 0.030 |
Why?
|
| Physician-Patient Relations | 1 | 2009 | 3246 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2016 | 20551 | 0.030 |
Why?
|
| Asymptomatic Diseases | 1 | 2019 | 587 | 0.030 |
Why?
|
| Molecular Conformation | 1 | 2016 | 545 | 0.030 |
Why?
|
| Disease Susceptibility | 1 | 2021 | 1790 | 0.030 |
Why?
|
| Mutant Proteins | 1 | 2016 | 491 | 0.030 |
Why?
|
| Radionuclide Imaging | 1 | 2018 | 1975 | 0.030 |
Why?
|
| Exosomes | 1 | 2018 | 424 | 0.030 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2016 | 452 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2012 | 7424 | 0.030 |
Why?
|
| HIV-1 | 1 | 2010 | 6859 | 0.030 |
Why?
|
| Chemokine CXCL12 | 1 | 2014 | 454 | 0.030 |
Why?
|
| Cytokines | 2 | 2018 | 7377 | 0.030 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2016 | 651 | 0.030 |
Why?
|
| Hospitalization | 1 | 2012 | 10698 | 0.020 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2016 | 611 | 0.020 |
Why?
|
| Genomic Instability | 1 | 2015 | 709 | 0.020 |
Why?
|
| Neoplastic Stem Cells | 1 | 2019 | 1347 | 0.020 |
Why?
|
| Serum | 1 | 2012 | 210 | 0.020 |
Why?
|
| Mass Spectrometry | 1 | 2018 | 2189 | 0.020 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2016 | 786 | 0.020 |
Why?
|
| South America | 1 | 2011 | 179 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2015 | 1755 | 0.020 |
Why?
|
| Drug Therapy | 1 | 2013 | 503 | 0.020 |
Why?
|
| Structure-Activity Relationship | 1 | 2016 | 3075 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2008 | 5835 | 0.020 |
Why?
|
| Transcriptional Activation | 1 | 2016 | 1753 | 0.020 |
Why?
|
| Prednisolone | 1 | 2011 | 326 | 0.020 |
Why?
|
| Hydrocarbons, Chlorinated | 1 | 2011 | 120 | 0.020 |
Why?
|
| Watchful Waiting | 1 | 2013 | 491 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2009 | 26280 | 0.020 |
Why?
|
| DNA Repair | 1 | 2018 | 2044 | 0.020 |
Why?
|
| Inflammation Mediators | 1 | 2018 | 1886 | 0.020 |
Why?
|
| Plasma Exchange | 1 | 2010 | 158 | 0.020 |
Why?
|
| Vitamin B 12 Deficiency | 1 | 2010 | 118 | 0.020 |
Why?
|
| Device Removal | 1 | 2013 | 630 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2018 | 2723 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2014 | 3592 | 0.020 |
Why?
|
| Drug Discovery | 1 | 2016 | 1054 | 0.020 |
Why?
|
| Pregnancy | 1 | 2009 | 29831 | 0.020 |
Why?
|
| Interferon Regulatory Factors | 1 | 2009 | 262 | 0.020 |
Why?
|
| Vitamin B 12 | 1 | 2010 | 524 | 0.020 |
Why?
|
| Plasma | 1 | 2010 | 585 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2015 | 6086 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2011 | 2281 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2016 | 3209 | 0.020 |
Why?
|
| Anticoagulants | 1 | 2022 | 4806 | 0.020 |
Why?
|
| Cardiomyopathies | 1 | 2018 | 1957 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2016 | 5427 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2015 | 6297 | 0.020 |
Why?
|
| Epigenesis, Genetic | 1 | 2018 | 3782 | 0.020 |
Why?
|
| Alleles | 1 | 2016 | 6908 | 0.020 |
Why?
|
| Family | 1 | 2016 | 3189 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2016 | 5778 | 0.020 |
Why?
|
| Breast | 1 | 2013 | 1962 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 2015 | 4735 | 0.010 |
Why?
|
| Models, Genetic | 1 | 2014 | 3445 | 0.010 |
Why?
|
| Liver | 1 | 2019 | 7531 | 0.010 |
Why?
|
| Peptide Fragments | 1 | 2016 | 5105 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 15257 | 0.010 |
Why?
|
| Graft Survival | 1 | 2013 | 3806 | 0.010 |
Why?
|
| DNA Methylation | 1 | 2016 | 4383 | 0.010 |
Why?
|
| Fellowships and Scholarships | 1 | 2009 | 1117 | 0.010 |
Why?
|
| Genetic Variation | 1 | 2016 | 6570 | 0.010 |
Why?
|
| Graft vs Host Disease | 1 | 2013 | 3028 | 0.010 |
Why?
|
| Data Collection | 1 | 2009 | 3321 | 0.010 |
Why?
|
| Pandemics | 1 | 2020 | 8623 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2018 | 15867 | 0.010 |
Why?
|
| Research Design | 1 | 2013 | 6168 | 0.010 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2010 | 4369 | 0.010 |
Why?
|
| Attitude of Health Personnel | 1 | 2009 | 3880 | 0.010 |
Why?
|
| Communication | 1 | 2009 | 3868 | 0.010 |
Why?
|